The invention provides bifunctional compounds of formula (I) or a pharmaceutically acceptable salt thereof. Formula (I). The compounds cause the degradation of SMARCA2 via the targeted ubiquination of SMARCA2 protein and subsequent proteasomal degradation and are thus useful for the treatment of cancer. The targeting ligand is of formula (TL).
该发明提供了式(I)的双功能化合物或其药用可接受的盐。式(I)。这些化合物通过靶向泛素化SMARCA2蛋白并随后的
蛋白酶体降解来导致SMARCA2的降解,因此对于癌症的治疗是有用的。靶向
配体的
化学式为(TL)。